<DOC>
	<DOCNO>NCT00727857</DOCNO>
	<brief_summary>The purpose study determine efficacy pioglitazone , twice daily ( BID ) , combine metformin versus pioglitazone take alone metformin take alone treat Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Efficacy Safety Pioglitazone Metformin Combination Therapy Treating Type 2 Diabetes Mellitus .</brief_title>
	<detailed_description>Pioglitazone hydrochloride ( ACTOSÂ® ) member class oral antidiabetic agent know thiazolidinediones , act reduce insulin resistance . Insulin resistance key feature dysmetabolic syndrome suggest common pathophysiologic basis atherosclerosis type 2 diabetes . Pioglitazone bind peroxisome proliferator-activated receptor , effect associate altered transcription gene capable influence carbohydrate lipid metabolism . Metformin hydrochloride oral antihyperglycemic drug chemically pharmacologically related thiazolidinediones . Metformin biguanide , show effective improve glycemic control diabetic patient . Metformin inhibit hepatic glucose production , likely inhibition gluconeogenesis , use associate improvement tissue sensitivity insulin . In accordance publish algorithms use combination therapy treatment type 2 diabetes , physician traditionally combine metformin antidiabetic agent . This study determine effect fixed-dose combination metformin pioglitazone , compare metformin monotherapy pioglitazone monotherapy . Study participation anticipate approximately 6.5 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion Criteria Has type 2 diabetes . Has receive treatment antidiabetic medication 12 week prior Screening , shortterm use define less equal 15 day . A glycosylated hemoglobin great equal 7.5 % less equal 10.0 % Screening . Body mass index less equal 45 kg/m2 . Has receive counsel lifestyle modification type 2 diabetes , include diet exercise . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Stable condition determine physician . Exclusion Criteria Type 1 diabetes . Unstable angina heart failure etiology New York Heart Association functional class III IV . History myocardial infarction , cerebrovascular accident , percutaneous coronary intervention , coronary artery bypass graft , transient ischemic attack 6 month prior Screening . Male participant serum creatinine level great equal 1.5 mg per dL female subject serum creatinine level great equal 1.4 mg per dL . Has triglyceride level great 500 mg per dL . Male participant hemoglobin level le 10.5 g per dL female subject hemoglobin level less 10.0 g per dL . Alanine aminotransferase level great 2.5 time upper limit normal , active liver disease , jaundice . History drug abuse ( define illicit drug use ) history alcohol abuse ( define regular daily consumption 2 alcoholic drink per day ) within 2 year prior Screening . Has discontinue thiazolidinedione metformin therapy due lack efficacy clinical laboratory sign intolerance . Previous history cancer , basal cell stage 1 squamous cell carcinoma , remission least 5 year prior first dose study medication . History acute chronic metabolic acidosis , include diabetic ketoacidosis without coma . Any disease condition Screening Randomization would compromise safety , might affect life expectancy , make difficult successfully manage follow subject accord protocol . Currently participate another investigational study participate investigational study within 30 day prior randomization . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Antidiabetic medication study medication Chronically use oral parenteral glucocorticoid Niacin great 200 mg per day , include niacincontaining product Advicor Chronically use steroidjoint injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus , Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>